The CaP CURE 7th Annual Scienti®c Retreat was held on the 21±24 September 2000 at Incline Village, Nevada, USA. The meeting represented the world's largest gathering of scientists, physicians and advocates focused on ending prostate cancer. Dr Owen Witte from the University of California, USA, presented a state-of-theart lecture on the use of prostate stem cell antigen (PSCA) as a marker for prostate cancer, the highlights of which are summarised.
Little is known about the prostate stem cell and markers and assays are needed to look at it in the physical and biological sense. One of the goals for this type of research is to look at the growth control mechanisms that the normal prostatic stem and progenitor cell elements would use and see how these are abnormally regulated to create prostate cancer. Novel therapeutic approaches could be developed by targeting the expression of abnormal surface cell antigens and pathways.
In normal prostate development in humans, the basal cell compartment gives rise to the epithelial component and somewhere along this pathway genetic abnormalities lead to the development of prostate cancer. Cells leave the prostate and go to distal sites, such as lymph nodes or bone and carry on autonomous growth. Markers for early basal cells have been identi®ed that continue to be expressed, or whose level of expression changes during the development of prostate cancer. One such marker is PSCA, a GPI-anchored cell surface protein that is predominantly expressed in the prostate at the mRNA level. Its expression is correlated with higher tumour stage and grade, being expressed in 80% of cases of prostate cancer, as well as to metastatic prostate cancer and androgen independence. Increased expression is usually not linked to an increased copy number of the gene.
Monoclonal antibodies to PSCA have been prepared by Dr Robert Reiter and together with a murine model have assisted in identifying the mechanism for increased expression of PSCA. A transgenic strain of mouse was developed by Dr Tetsuro Watabe, in which a fragment of the human genomic sequence upstream of the human PSCA gene was used to drive expression of the green uorescent protein (GFP). The objective was to study how this gene was turned on or off with various growth manipulations. Expression of GFP in the mouse prostate was found to be associated with regions of the prostate containing stem-and progenitor-like elements.
In the TRAMP mouse model, in which prostate cancer develops, positive staining for GFP was observed. This suggests that GFP could be used as a growth marker for the prostate and for prostate cancer itself. It is questionable as to whether the transcriptional changes in GFP were linked to the endogenous protein level of PSCA. Anti-PSCA antibodies show increased staining in prostates from the TRAMP model, suggesting that some genetic effect in the TRAMP model is turning on expression of this protein. Other models studied include PTEN knock out mouse, the heterozygote form of which develops a widerange of tumours. In the prostate cancer model, at 12 months there is very strong staining for PSCA.
These ®ndings raise the issue that although PSCA is being expressed during the process of prostate cancer growth, is it useful as a marker, for example, in dictating therapy. A human xenograph model was studied involving orthotopic injection into the prostate and evaluation of how various antibodies affect the growth of tumours. In one study, conducted in collaboration with Dr Doug Saffran and Dr Aya Jakobovits at Urogenesys, a privately held biotechnology company, animals were simultaneously inoculated with tumour and various doses of the monoclonal antibody 1G8. Using PSCA level as a surrogate marker for tumour growth, the antibody appeared to stop the growth of the tumour, which was reversible on cessation of antibody treatment. The 1G8 antibody has also been shown to reduce the number of metastases in this animal model. Dr Witte concluded that we still do not know much about what the stem cell progenitors for the prostate are, but markers for them are being identi®ed, which may be useful for treatment.
Vaccine therapy for prostate cancer
An interview was conducted with Dr Al Boynton, NW Therapeutics, Seattle, Washington, USA, on his research in vaccine therapy for prostate cancer.
What is the basis for vaccine therapy in prostate cancer?
A viable vaccine for prostate cancer is dependent on at least two important components. First, it is imperative to incorporate an effective means of stimulating the immune system. The most logical approach is to replicate the process of how the human immune system begins. Fortunately, the progress in immunology during the last decade has adequately de®ned this process so that technologies have now been developed that can be employed to stimulate the immune response from the earliest stages. Second, a target antigen to which the immune response is directed is essential. The antigen should have a high degree of speci®city to the prostate or to the prostate tumour cells. The number of tumour associated antigens is increasing due to the concentrated efforts of antigen discovery and de®nition of the human genome. Ideally, the antigen should be prostate tumour speci®c; however, in reality, a high degree of speci®city to the prostate is adequate for selection as a target.
How far advanced is the research in this area?
Signi®cant strides have been made in the therapeutic vaccine area during the last 5 years, both in the mechanism by which to stimulate the immune response speci®-cally against prostrate antigens and in the identi®cation of highly speci®c prostate antigens. Fortunately, the prostate is a non-essential tissue, thus directing an immune response to the prostate with the goal of destroying prostate cells should not compromise health. The cellular immune response is now known to be initiated by cells called dendritic cells (DCs) . The DCs are the most potent antigen presenting cell known today and they function by taking up, processing antigens and presenting antigenic peptides on their cell surface where interaction with naõ Ève T-cells occurs. Both a CD4 and CD8 T-cell response is elicited and proof-of-principle experiments in animal model systems support this approach. Key to the application of such a therapeutic vaccine in humans is the ability to isolate and manipulate human DCs. These cells can be isolated from monocyte precursors in vitro, loaded with puri®ed antigens and when added to T-cells stimulate antigen speci®c reactivity. Clinical trials carried out to date are encouraging with response rates against various cancers ranging from about 20% to greater than 60%.
Do you see there being a vaccine on the market within the next decade?
Personally, I would be surprised if a therapeutic vaccine were not on the market in the next 2 to 3 years. All the pieces are there, such as how to stimulate the immune system, what antigen to target on the tumour cells and importantly how to accomplish this in a cost-effective manner. Biological therapies are inherently more expensive to produce compared with off the shelf drugs currently used to treat prostate and other cancers. The DCbased approach is essentially a designer therapy with all components of the therapeutic vaccine being autologous. While this may seem to create an arduous production scheme, it actually turns out to be of great bene®t because the therapy is without adverse side-effects. When this is considered in comparison to current chemotherapeutic agents and side-effects associated with nonspeci®c cell killing, DC-based therapies are attractive and of obvious advantage as long as ef®cacy is comparable.
What research is being conducted at Northwest Biotherapeutics on prostate cancer vaccines?
Northwest Biotherapeutics, Inc. has developed DCVax TM ', a platform technology for isolation and processing of DCs that can be applied to virtually any cancer. DCVax TM -prostate represents our initial cancer target and is for hormone refractory prostate cancer. Thus, we are stimulating the immune system from its origin by DCs. The tumour-associated antigen we are targeting is prostate-speci®c membrane antigen (PSMA). This antigen is present in virtually all prostate tumours, is highly speci®c to prostate cells and thus represents an excellent target for immune-based therapies. Phase I/II clinical trials for hormone refractory prostate cancer are being conducted at the University of California, Department of The study comprised 30 samples from patients with benign prostatic hyperplasia (BPH) and 82 with prostate cancer. Assay of the two proteins was by means of immunohistochemistry and, in some instances, immunoblotting. Results showed that COX-1 and -2 were differentially expressed in benign prostates and that the expression of COX-2 differed signi®cantly in BPH and prostate cancer samples. COX-2 was expressed in luminal glandular epithelial cells of BPH and in the neoplastic epithelial cells of prostate cancers. However, the level of expression in the epithelial cells of prostate cancers was signi®cantly higher than that in BPH. These results would suggest the potential for targeting COX-2 as a therapeutic option. Several population-based studies have already shown that the regular use of aspirin and other nonsteroidal anti-in¯ammatories (NSAIDs) results in a signi®cant decrease in the relative risk of colorectal cancer (Thun et al, Gastroenterol Clin North Am 1996; 25: 333±348). More recent data indicate that regular use of NSAIDs reduced the risk of advanced prostate cancer (Norrish et al, Int J Cancer 1998; 77: 511±515). The relevance of this to the present ®nding is that NSAIDs act through inhibition of COXs.
COX-2 inhibition suppresses prostate cancer cells
Researchers at Mount Sinai School of Medicine, NY, USA have shown that inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo (Liu XH et al, J Urol 2000; 164: 820±825). COX-2 is an inducible enzyme that catalyzes the formation of prostaglandins from arachidonic acid. It is expressed in prostate cancer specimens and cell lines. A novel COX-2 inhibitor, NS398, was administered to mice inoculated with the PC-3 human prostate cancer cell line. Tumours were measured at weekly intervals. After a 10-week experimental period, tumours were assayed for proliferation (PCNA), apoptosis (TUNEL), microvessel density (MVD) and vascular epithelial growth factor (VEGF).
Results showed that NS398 induced a sustained inhibition of PC-3 tumour cell growth and a regression of existing tumours. NS398 had no effect on proliferation, but induced apoptosis and decreased MVD (measure of angiogenesis). VEGF expression was also signi®cantly down regulated in the NS398-treated tumours. The authors concluded that this selective COX-2 inhibitor suppresses PC-3 cell tumour growth in vivo. This suppression is achieved by a combination of direct induction of tumour cell apoptosis and down regulation of tumour VEGF with decreased angiogenesis.
High-dose radiotherapy improves outcome of localised prostate cancer
Higher doses of radiation have been reported to improve survival in patients with localised prostate cancer (Valicenti et al, J Clin Oncol 2000; 18: 2740±2746) . From 1975 to 1992, 1465 men with clinically localised prostate cancer received external beam radiation therapy in four Radiation Therapy Oncology Group phase III randomised trials; results of these studies were pooled for analysis. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy); median follow-up time was 8 y.
Results indicated that Gleason score was a independent predictor of disease-speci®c survival and overall survival. The 10-year disease-speci®c survival rates by Gleason score were as follows: score 2±5: 86%; score 6: 79%; score 7: 62%; and score 8±10: 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a signi®cant predictor for improved disease-speci®c survival and overall survival only for those patients whose cancer had Gleason scores of 8±10 (P`0.05). After adjusting for clinical T-stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P`0.05). The authors concluded that higher-dose radiation therapy can signi®cantly reduce the risk of dying from prostate cancer in men with clinically localised disease. However, this survival bene®t is restricted to men with poorly differentiated cancers.
Outcome of radiation therapy improved with the addition of androgen blockade
Research has been published showing that combined therapy for clinically localised prostate cancer of radiotherapy plus androgen is associated with a better outcome than radiotherapy alone (D'Amico AV et al, JAMA 2000; 284: 1280±1283). The study was a retrospective cohort study of 1586 men treated with 3D conformal radiotherapy with (n 276) or without (n 1310) 6 months of androgen suppression therapy. Assessed were relative risk (RR) of prostate-speci®c antigen (PSA) failure by treatment and high-, intermediate-, or low-risk group based on serum PSA level, biopsy Gleason score, and 1992 American Joint Commission on Cancer clinical tumour category.
Results showed that estimates of 5-year PSA outcome after radiotherapy with or without androgen blockade were not statistically different among low-risk patients (P 0.09), whereas intermediate-and high-risk patients treated with radiotherapy plus androgen blockade had signi®cantly better outcomes than those treated with radiotherapy alone (P`0.001 and 0.009, respectively). There was a 5-and 2.5-fold reduction in relative risk for PSA failure in the intermediate and high-risk groups, respectively, treated with the combined modality compared with radiotherapy alone.
The authors concluded that there was a signi®cant bene®t in 5-year PSA outcomes for men with clinically localised prostate cancer in intermediate-and high-risk groups treated with radiotherapy plus androgen blockade.
Prospective randomised trials are currently under way to validate these ®ndings.
Impotence more common after radical prostatectomy than previously thought A recently published study on the follow-up after radical prostatectomy suggests that impotence occurs far more frequently than previously reported, which has been as low as 20% (Stanford JL et al. JAMA 2000; 283: 354±360) . This ®rst nationally representative study of long-term outcomes after prostate surgery was conducted in 1291 men aged 39±79 from six National Cancer Institute cancer registries in the US. A higher proportion of cases among black men, Hispanic men and men aged under 65 y were deliberately included as research in these groups has previously been limited. Men included in the survey had all undergone radical prostatectomy for localised prostate cancer between 1994 and 1995. The study was considered to be more comprehensive than previous ones as they usually involved a single surgeon or institution, or a limited patient population.
Researchers found that 60% of treated men were impotent 18 months after surgery, 8% experienced total urinary incontinence and 40% had occasional genitourinary problems. Of men receiving a non-nerve sparing procedure, 66% said they were impotent after surgery compared with 56% who had a bilateral nerve sparing procedure and 59% the unilateral operation. Interestingly, the study also showed marked differences in the rates of impotence reported by different racial groups. Potency was reported in 38% of black men at 18 months or more after surgery, compared with 26% of Hispanic men and 21% of Caucasians.
Although 42% of the study group considered sexual function after surgery to be a`moderate to big' problem, three-quarters said that they were pleased with the surgery and 72% said they would choose radical prostatectomy again.
The study's leader, Dr Janet Stanford, suggested that the accuracy of these new data should help men to better balance the risks and bene®ts of radical prostatectomy.
Phytotherapeutic agent PC-SPES: ef®cacy in prostate cancer
A recent clinical trial reports that the phytotherapy PC-SPES has activity in prostate cancer patients (de la Taille A et al, J Urol 2000; 164: 1229±1234). A total of 69 patients with prostate cancer were treated with three capsules of 320 mg PC-SPES daily. Serum PSA responses and sideeffects were evaluated. A total of 82% of patients had decreased serum PSA at 2 months, 78% at 6 months and 88% at 12 months after treatment with PC-SPES. Sideeffects included nipple tenderness in 42% and phlebitis requiring heparinisation in 2%. PC-SPES was also evaluated for its ability to induce apoptosis in prostate cancer cell lines LNCaP, PC3 and DU145. The effect of oral PC-SPES on growth of PC3 tumours present in male immunode®cient mice was studied. Results showed that all of the cultured prostate cancer cell lines had a signi®cant dose-dependent induction of apoptosis following exposure to PC-SPES extract. Immunode®cient mice xenografted with the PC3 cell line had reduced tumour volume compared with sham treated controls when they were treated with a PC-SPES extract from the time of tumour cell implantation, but not when the treatment was begun 1 week after tumour cell implantation. The testes, prostate, bladder and seminal vesicles of the treated mice were signi®cantly reduced in weight compared with the sham treated animals.
The authors conclude that treatment of prostate cancer patients with PC-SPES causes a decrease in serum PSA in the majority and is associated with a side-effect pro®le comparable to oestrogen treatment. In vitro, PC-SPES is active in inducing apoptosis of hormone sensitive and insensitive prostate cancer cells, and in suppressing the growth rate of a hormone insensitive prostate cancer cell line in vivo.
Tumour suppressor genes identi®ed in prostate cancer cells More recent studies describe a role for maspin in inhibition of angiogenesis. This new research indicates that the well-known tumour suppressor gene, p53, plays a role in regulating maspin expression in cells. Consequently, any defects in p53 expression are likely to result in more aggressive cancers. Future research should focus on a better understanding of how p53 and maspin actually interact and how to correct defects in the maspin/p53 pathway in cancer cells.
